



## Patient Information (required)

Patient ID (Medical Record No.)	Client Account No.
Patient Name (Last, First Middle)	Client Order No.
Birth Date (mm-dd-yyyy)	

**Hematopathology Consultation**

PATHC Pathology Consultation (submit PB and bone marrow aspirate slides, block)

HPWET Hematopathology Consultation, MCL Embed (submit core biopsy, clot section, bone marrow aspirate and PB slides)

HPCUT Hematopathology Consultation, Client Embed (submit bone marrow liquid aspirate, PB and bone marrow slides and embedded core biopsy and clot section)

**Note: HPWET and HPCUT require MCL approval prior to ordering and submission of specimens. Call 800-533-1710 for approval.**

**Hematologic Disorders Hold Service**

HOLDC Chromosome Hold

HOLDF Fluorescence In Situ Hybridization (FISH) Hold

HLLFH Leukemia/Lymphoma Flow Hold\*\*\*

EXHD DNA Extract and Hold

EXHR DNA and RNA Extract and Hold

**Flow Cytometry**

Leukemia/Lymphoma Immunophenotyping

LCMS Blood/Bone Marrow\*\*\*

LLTOF Blood/Bone Marrow, Technical Only

LLPT Tissue (with interpretation)

LLTOT Tissue, Technical Only

MYEFL Myelodysplastic Syndrome by Flow Cytometry, Bone Marrow

PLINK Paroxysmal Nocturnal Hemoglobinuria, PI-Linked Antigen, Blood

SZDIA Sezary Diagnostic Flow Cytometry, Blood

SZMON Sezary Monitoring Flow Cytometry, Blood

CEE20 CD20 Cell Expression Evaluation

CEE49 CD49d Cell Expression Evaluation

CEE52 CD52 Cell Expression Evaluation

**Chromosome Analysis**

CHRBM Hematologic Disorders, Bone Marrow

CHRHB Hematologic Disorders, Blood

**Next-Generation Sequencing (NGS)**

NGAML MayoComplete Acute Myeloid Leukemia, 11-Genes Panel

NGAMT MayoComplete Acute Myeloid Leukemia, Therapeutic Gene Mutation Panel (FLT3, IDH1, IDH2, TP53), NGS

NGBCL MayoComplete B-Cell Lymphoma, NGS

NGCLN MayoComplete Chronic Lymphoid Neoplasms, NGS

NGHIS MayoComplete Histiocytic Neoplasms, NGS

NGSHM MayoComplete Myeloid Neoplasms, Comprehensive OncoHeme Next-Generation Sequencing

NGPCM MayoComplete Plasma Cell Myeloma, NGS

NGSFX Reanalysis, AML 4 or 11 Gene Panel, Additional Genes

NGTCL MayoComplete T-Cell Lymphoma, NGS

**Chromosomal Microarray**

CMAH Hematologic Disorders

### ACUTE MYELOID LEUKEMIA (AML)/ MYELOYDYSPLASTIC SYNDROME (MDS)

**Acute Myeloid Leukemia (AML)**

FLT FLT3 Mutation Analysis

IDHQ IDH1 (R132) and IDH2 (R140 and R172) Quantitative Detection, Droplet Digital PCR

IN16Q CBF- MYH11 Inversion(16), Quantitative Detection and Minimal Disease Risk Monitoring, qRT-PCR

NGAML MayoComplete Acute Myeloid Leukemia, 11-Genes Panel

NGAMT MayoComplete Acute Myeloid Leukemia, Therapeutic Gene Mutation Panel (FLT3, IDH1, IDH2, TP53), Next-Generation Sequencing

NPM1Q Nucleophosmin (NPM1) Mutation Analysis

NGSHM MayoComplete Myeloid Neoplasms, Comprehensive OncoHeme Next-Generation Sequencing

PMLR PML::RARA Quantitative, PCR, Varies

T821Q RUNX1-RUNX1T1 Translocation (8;21), Minimal Residual Disease Monitoring, Quantitative

AMLFA Adult Acute Myeloid Leukemia Panel, FISH

AMLFP Pediatric Acute Myeloid Leukemia Panel, FISH

AMLMF Acute Myeloid Leukemia (AML), Specified FISH

For AMLMF: must specify probe sets to be performed.

RUNX1T1/RUNX1 t(8;21)(q21;q22)

BAP RUNX1 21q22 rearrangement

PML/RARA t(15;17)(q24.1;q21.2)

RARA/BAP 17q21 rearrangement

KMT2A BAP 11q23 rearrangement

AFF1/KMT2A t(4;11)(q21;q23)

AFDN/KMT2A t(6;11)(q27;q23)

MLLT3/KMT2A t(9;11)(p21;q23)

MLLT10/KMT2A t(10;11)(p13;q23)

KMT2A/CREBBP t(11;16)(q23;p13.3)

KMT2A/ELL t(11;19)(q23;p13.3)

MYH11/CBFB inv(16)(p13q22) or t(16;16)

CBFB BAP 16q22 rearrangement

GLIS2/CBFA2T3 inv(16)(p13q24)

NUP98 BAP 11p15.4 rearrangement

MNX1/ETV6 t(7;12)(q36;p13)

DEK/NUP214 t(6;9)(p22;q34)

GATA2/MECOM inv(3)(q21.3q26.2) or t(3;3)

MECOM BAP 3q26 rearrangement

PRDM16/GATA2 t(1;3)(p36.3;q21.3)

KAT6A/CREBBP t(8;16)(p11.2;p13.3)

D5S630/EGR1 -5/5q deletion

D7Z1/D7S486 -7/7q deletion

TP53/D17Z1 -17/17p deletion

BCR/ABL1 t(9;22)(q34;q11.2)

ABL1 BAP 9q34 rearrangement

**Myelodysplasia Syndromes (MDS)**

MDSDF Myelodysplastic Syndrome (MDS), Diagnostic FISH

MDSMF Myelodysplastic Syndrome (MDS), Specified FISH

For MDSMF: **must** specify probe sets to be performed.

GATA2/MECOM inv(3)(q21.3q26.2) or t(3;3)

PRDM16/GATA2 t(1;3)(p36.3;q21.3)

D5S630/EGR1 -5/5q deletion

D7Z1/D7S486 -7/7q deletion

D8Z2/MYC +8

TP53/D17Z1 -17/17p deletion

D20S108/20qter -20/20q deletion

MYEFL Myelodysplastic Syndrome by Flow Cytometry, Bone Marrow

PLINK PNH, PI-Linked Antigen, Blood

MSTF Myeloid Sarcoma, FISH, Tissue

Must select probes listed below or entire panel.

RUNX1T1/RUNX1 t(8;21)(q21;q22)

BCR/ABL1 t(9;22)(q34;q11.2)

KMT2A BAP 11q23 rearrangement

PML/RARA t(15;17)(q24.1;q21.2)

MYH11/CBFB inv(16)(p13q22) or t(16;16)

**Perform entire panel**

UBA1Q UBA1 Mutation Quantitative Detection, VEXAS syndrome, Droplet Digital PCR

**Patient Information (required)**

Patient ID (Medical Record No.)	Client Account No.
Patient Name (Last, First Middle)	Client Order No.
Birth Date (mm-dd-yyyy)	

**BONE MARROW TRANSPLANT**

BALLM B-Cell Lymphoblastic Leukemia Monitoring, Minimal Residual Disease Detection, Flow Cytometry

CHIDB Chimerism-Donor

CHRGB Chimerism-Recipient Germline (Pretransplant)

CHIMU Chimerism Transplant No Cell Sort

CHIMS Chimerism Transplant Sorted Cells

CLLMD Chronic Lymphocytic Leukemia (CLL) Monitoring Minimal Residual Disease Detection, Flow Cytometry

1DIS HLA A-B-C Disease Association Typing Low Resolution, Blood

2DIS HLA-DR-DQ Disease Association Typing Low Resolution, Blood

**LYMPHOID DISORDERS**

**B Cell**

BALLM B-Cell Lymphoblastic Leukemia Monitoring, Minimal Residual Disease Detection, Flow Cytometry

Immunoglobulin Gene Rearrangement

BCGR Blood

BCGBM Bone Marrow

BCGRV Varies

NGBCL MayoComplete B-Cell Lymphoma, Next-Generation Sequencing

NGCLN MayoComplete Chronic Lymphoid Neoplasms, Next-Generation Sequencing

MYD88 MYD88, L265P, Somatic Gene Mutation, DNA Allele-Specific PCR

CXLPL CXCR4 Mutation Analysis, Somatic, Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia

LPLFX Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia, MYD88 L265P with Reflex to CXCR4

SVISC Viscosity, Serum

BLBLF B-Cell Lymphoblastic Leukemia/Lymphoma, FISH, Tissue

For BLBLF: **must** specify probe sets to be performed.

BCR/ABL1 t(9;22)

KMT2A/BAP 11q23 rearrangement

PBX1/TCF3 t(1;19)(q23;p13)

D4Z1/D10Z1/D17Z1 Hyperdiploidy, +4,+10,+17

ETV6/RUNX1 fusion and iAMP21 t(12;21)(p13;q22)

IGH break-apart 14q32 rearrangement

MYC break-apart 8q24.2

MYC/IGH fusion t(8;14)(q24.2;q32)

ABL2 break-apart 1q25 rearrangement

PDGFRB break-apart 5q32 rearrangement

JAK2 break-apart 9p24.1 rearrangement

ABL1 break-apart 9q34 rearrangement

**Perform entire panel**

PHLFD B-Lymphoblastic Leukemia/Lymphoma with BCR::ABL1-like Features Panel, FISH

BALAF B-Cell Acute Lymphoblastic Leukemia/Lymphoma (ALL), FISH, Adult

BALFP Pediatric B-Lymphoblastic Leukemia/Lymphoma Panel, FISH

BALMF B-Cell Acute Lymphoblastic Leukemia/Lymphoma (ALL), Specified FISH

For BALMF: **must** specify probe sets to be performed.

ABL2 break-apart 1q25 rearrangement

PDGFRB break-apart 5q32 rearrangement

IKZF1/CEP7 7p-

JAK2 break-apart 9p24.1 rearrangement

BCR/ABL1 t(9;22)(q34;q11.2)

ABL1 break-apart 9q34 rearrangement

KMT2A/BAP 11q23 rearrangement

AFF1/KMT2A t(4;11)(q21;q23)

AFDN/KMT2A t(6;11)(q27;q23)

MLLT3/KMT2A t(9;11)(p21;q23)

MLLT10/KMT2A t(10;11)(p13;q23)

KMT2A/ELL t(11;19)(q23;p13.1)

KMT2A/MLLT1 t(11;19)(q23;p13.3)

PBX1/TCF3 t(1;19)(q23;p13)

D4Z1/D10Z1/D17Z1 +4,+10,+17, Hyperdiploidy

ETV6/RUNX1 & iAMP21 t(12;21)(p13;q22)

ETV6 break-apart 12p13 rearrangement

IGH break-apart 14q32 rearrangement

P2RY8 rearrangement t(Xp22.33;var) or t(Yp11.32;var)

CRLF2 rearrangement t(Xp22.33;var) or t(Yp11.32;var)

CRLF2/IGH t(X;14)(p22.33;q32) or t(Y;14)(p11.32;q32)

MYC break-apart 8q24.2 rearrangement

MYC/IGH fusion t(8;14)(q24.2;q32)

BCL6 BAP 3q27 rearrangement

BCL2 BAP 18q21 rearrangement

IGH/BCL2 t(14;18)(q32;q21)

BLPMF B-Cell Lymphoma, Specified FISH

For BLPMF: **must** specify probe sets to be performed. If not specified, probes tested will be determined based on reason for testing.

MYC break-apart 8q24.2 rearrangement

IGK/MYC fusion t(2;8)(p12;q24.2)

MYC/IGH fusion t(8;14)(q24.2;q32)

MYC/IGL fusion t(8;22)(q24.2;q11.2)

BCL6 break-apart t(3q27;var) rearrangement

IGH/BCL2 t(14;18)(q32;q21)

BCL2 break-apart t(18q21;var) rearrangement

CCND1/IGH fusion t(11;14)(q13;q32)

TP53/D17Z1 -17/17p deletion

D7Z1/7q32 7q32 deletion

BLYM B-Cell Lymphoma, FISH, Tissue  
*Must select lymphoma subtype.*

**Burkitt (Pediatric)**

Must select probes listed below or entire panel.

MYC break-apart 8q24.2 rearrangement

IGK/MYC t(2;8)(p12;q24.2)

MYC/IGH t(8;14)(q24.2;q32)

MYC/IGL t(8;22)(q24.2;q11.2)

BCL6 break-apart 3q27 rearrangement

BCL2 break-apart 18q21 rearrangement

**Perform entire Burkitt panel**

**Diffuse Large B-Cell, Burkitt-Like "Double-Hit"**

Must select probes listed below or entire panel.

MYC break-apart 8q24.2 rearrangement

MYC/IGH t(8;14)(q24.2;q32)

reflex: IGK/MYC t(2;8)(p12;q24.2)

reflex: MYC/IGL t(8;22)(q24.2;q11.2)

reflex: BCL6 BAP 3q27 rearrangement

reflex: BCL2 BAP 18q21 rearrangement

reflex: IGH/BCL2 t(14;18)(q32;q21)

**Perform entire frontline "Double-Hit" panel**

**Follicular**

Must select probes listed below or entire panel.

BCL2 BAP 18q21 rearrangement

BCL6 BAP 3q27 rearrangement

TNFRSF14/1q22 deletion of 1p36

**Perform entire follicular panel**

## Patient Information (required)

Patient ID (Medical Record No.)	Client Account No.
Patient Name (Last, First Middle)	Client Order No.
Birth Date (mm-dd-yyyy)	

**Histiocytic**

**NGHIS** MayoComplete Histiocytic Neoplasms, Next-Generation Sequencing

**Mantle Cell**

**CCND1/IGH** t(11;14)(q13;q32)

**CCND1 break-apart** 11q13 rearrangement

**TP53/D17Z1** Blastoid subtype only: deletion of 17p

**MYC break-apart** Blastoid subtype only: 8q24.2 rearrangement

**CCND2 break-apart** Cyclin D1-negative subtype only: 12p13.32 rearrangement

**Perform entire frontline Mantle Cell panel**

**Splenic Marginal Zone Lymphoma (SMZL)**

Must select probes listed below or entire panel.

**D7Z1/7q32** 7q32 deletion

**TP53/D17Z1** -17/17p deletion

**Perform entire SMZL panel**

**Mucosa-Associated Lymphoid Tissue (MALT/ENMZL) (BLYM only)**

**MALT1 break-apart** 18q21 rearrangement

**Large B-Cell with IRF4 Rearrangement (BLYM only)**

Must select probes listed below or entire panel.

**IRF4 break-apart** 6p25.3 rearrangement

**BCL2 break-apart** 18q21 rearrangement

**reflex: IGH/BCL2** t(14;18)(q32;q21)

**BCL6 break-apart** 3q27 rearrangement

**Perform entire Large B-Cell panel**

**Chronic Lymphocytic Leukemia (CLL)**

**CLLMD** Chronic Lymphocytic Leukemia (CLL) Monitoring Minimal Residual Disease (MRD) Detection, Flow Cytometry

**BCLL** IGH Somatic Hypermutation Analysis, B-Cell Chronic Lymphocytic Leukemia (B-CLL)

**P53CA** Hematologic Neoplasms, TP53 Somatic Mutation, DNA Sequencing Exons 4–9

**CLLDF** Chronic Lymphocytic Leukemia, Diagnostic FISH

**CLLMF** Chronic Lymphocytic Leukemia, Specified FISH

**SLL** Small Lymphocytic Lymphoma, FISH, Tissue

For CLLMF, **must** specify probe sets to be performed. For SLL, **must** select **either** individual probes listed below or entire panel

**D6Z1/MYB** -6/6q deletion

**D11Z1/ATM** -11/11q deletion

**D12Z3/MDM2** +12

**D13S319/LAMP1** -13/13q deletion

**TP53/D17Z1** -17/17p deletion

**CCND1/IGH** t(11;14)(q13;q32)

**IGH/BCL3** t(14;19)(q32;q13)

**Perform entire panel**

**TLPFD** T-Cell Lymphoma Panel, Diagnostic, FISH

**TLPMF** T-Cell Lymphoma, Specified FISH

For TLPMF, **must** specify probe sets to be performed.

**TCL1A break-apart** 14q32.1/14q11.2 rearrangement

**TRA break-apart** 14q11.2 rearrangement

**D7Z1/D7S486** i(7q)

**D8Z2/MYC** +8

**TLYM** T-Cell Lymphoma, FISH, Tissue

Must select probes listed or entire panel.

**TCL1A BAP** 14q32.1 rearrangement

**TRA BAP** 14q11.2 rearrangement

**D7Z1/D7S486** -7/iso(7q)

**D8Z2/MYC** +8

**ALK BAP** 2p23 rearrangement

**TP63 BAP** 3q28 rearrangement

**IRF4 (DUSP22) BAP** 6p25.3 rearrangement

**Perform entire panel**

**T Cell**

**NGTCL** MayoComplete T-Cell Lymphoma, Next-Generation Sequencing

T-Cell Receptor Gene Rearrangement

**TCGR** PCR, Blood

**TCGBM** Bone Marrow\*\*\*

**TCGRV** Varies

**SZDIA** Sezary Diagnostic Flow Cytometry, Blood

**SZMON** Sezary Monitoring Flow Cytometry, Blood

**TALAF** T-Cell Acute Lymphoblastic Leukemia/ Lymphoma (ALL), FISH, Adult

**TALFP** Pediatric T-Lymphoblastic Leukemia/ Lymphoma Panel, FISH

**TALMF** T-Cell Acute Lymphoblastic Leukemia/ Lymphoma (ALL), Specified FISH

For TALMF, **must** specify probe sets to be performed.

**TAL1/STIL** 1p32 rearrangement

**TLX3/BCL11B** t(5;14)(q35;q32)

**PDGFRB break-apart** 5q32 rearrangement

**TRB break-apart** 7q34 rearrangement

**MYB/TRB** t(6;7)(q23;q34)

**TRB/TLX1** t(7;10)(q34;q24)

**TRB/LMO1** t(7;11)(q34;p15)

**TRB/LMO2** t(7;11)(q34;p13)

**JAK2 break-apart** 9p24.1 rearrangement

**ABL1/BCR** t(9;22) or ABL1 amplification

**ABL1 break-apart** 9q34 rearrangement

**MLLT10/PICALM** t(10;11)(p12;q14)

**KMT2A** 11q23 rearrangement

**AFF1/KMT2A** t(4;11)(q21;q23)

**AFDN/KMT2A** t(6;11)(q27;q23)

**MLLT3/KMT2A** t(9;11)(p21;q23)

**MLLT10/KMT2A** t(10;11)(p12;q23)

**KMT2A/ELL** t(11;19)(q23;p13.1)

**KMT2A/MLLT1** t(11;19)(q23;p13.3)

**TRA break-apart** 14q11.2 rearrangement

**MYC/TRA** t(8;14)(q24.2;q11.2)

**TLX1/TRA** t(10;14)(q24;q11.2)

**LMO1/TRA** t(11;14)(p15;q11.2)

**LMO2/TRA** t(11;14)(p13;q11.2)

**TLBLF** T-Lymphoblastic Leukemia/Lymphoma, FISH, Tissue

For TLBLF, **must** specify probe sets to be performed.

**TAL1/STIL** 1p33 rearrangement

**TLX3/BCL11B** t(5;14)(q35;q32)

**TRB break-apart** 7q34 rearrangement

**ABL1/BCR** t(9;22) or ABL1 amplification

**MLLT10/PICALM** t(10;11)(p12;q14)

**KMT2A break-apart** 11q23

**TRA break-apart** 14q11.2 rearrangement

## Patient Information (required)

Patient ID (Medical Record No.)	Client Account No.
Patient Name (Last, First Middle)	Client Order No.
Birth Date (mm-dd-yyyy)	

MYELOPROLIFERATIVE NEOPLASM (MPN)	
<b>BCR/ABL1 Testing</b>	
<b>Diagnostic</b>	
<input type="checkbox"/> BCRFX	BCR/ABL1 Qualitative Diagnostic Assay with Reflex to BCR/ABL1 p190 Quantitative Assay or BCR/ABL1 p210 Quantitative Assay
<input type="checkbox"/> BADX	BCR/ABL1, Qualitative, Diagnostic Assay***
<b>Monitoring</b>	
<input type="checkbox"/> BCRAB	BCR/ABL1, p210, mRNA Detection, Reverse Transcription-PCR (RT-PCR), Quantitative, Monitoring Chronic Myeloid Leukemia (CML)
<input type="checkbox"/> BA190	BCR/ABL1, p190, mRNA Detection, Reverse Transcription-PCR (RT-PCR), Quantitative, Monitoring Assay
<b>Additional</b>	
<input type="checkbox"/> BAKDM	BCR/ABL1, Tyrosine Kinase Inhibitor Resistance, Kinase Domain Mutation Screen, Sanger Sequencing
<b>JAK2-CALR-MPL-JAK2V617F Testing</b>	
<input type="checkbox"/> MPNR	Myeloproliferative Neoplasm, JAK2 V617F with Reflex to CALR and MPL
<input type="checkbox"/> PVJAK	Polycythemia Vera, JAK2 V617F with Reflex to JAK2 Exon 12-15, Sequencing for Erythrocytosis
JAK2 V617F Mutation Detection	
<input type="checkbox"/> JAK2B	Blood***
<input type="checkbox"/> JAK2M	Bone Marrow***
<input type="checkbox"/> JAK2V	Varies
<input type="checkbox"/> CALR	CALR Mutation Analysis, Myeloproliferative Neoplasm (MPN)***
<input type="checkbox"/> MPNCM	Myeloproliferative Neoplasm, CALR with Reflex to MPL
<input type="checkbox"/> MPLVS	MPL Exon 10 Mutation Detection
JAK2 Exon 12 and Other Non-V617F Mutation Detection	
<input type="checkbox"/> JAKXB	Blood***
<input type="checkbox"/> JAKXM	Bone Marrow

MISCELLANEOUS MYELOPROLIFERATIVE NEOPLASM (MPN)	
<input type="checkbox"/> EOSFD	Chronic Eosinophilia Panel, Diagnostic FISH
<input type="checkbox"/> EOSMF	Chronic Eosinophilia, Specified FISH
For EOSMF: <b>must</b> specify probe sets to be performed.	
<input type="checkbox"/> FIP1L1, CHIC2, PDGFRA break-apart	4q12 deletion or rearrangement
<input type="checkbox"/> PDGFRA break-apart	4q12 rearrangement
<input type="checkbox"/> PDGFRB break-apart	5q32
<input type="checkbox"/> FGFR1 break-apart	8p11.2 rearrangement
<input type="checkbox"/> JAK2 break-apart	9p24.1 rearrangement
<input type="checkbox"/> ABL1 break-apart	9q34 rearrangement
<input type="checkbox"/> BCR/ABL1	t(9;22)(q34;q11.2)
<input type="checkbox"/> FLT3 BAP	13q12.2 arrangement
<input type="checkbox"/> MURA	Lysozyme (Muramidase), Plasma
<b>KIT Mutation Testing</b>	
<input type="checkbox"/> KITQ	<i>KIT</i> p.Asp816Val Variant Analysis, Quantitative

MYELOMA, AMYLOIDOSIS, & DYSPROTEINEMIA	
<b>Amyloid</b>	
<input type="checkbox"/> AMPIP	Amyloid Protein Identification, Paraffin, Mass Spectrometry
<input type="checkbox"/> TTRX	Amyloidosis, Transthyretin-Associated Familial, Reflex, Blood
<input type="checkbox"/> FMTT	Familial Variant, Targeted Testing
<input type="checkbox"/> TTRZ	TTR Gene, Full Gene Analysis
<b>Myeloma</b>	
Is patient on CD38 Therapy? <input type="checkbox"/> Yes <input type="checkbox"/> No	
<input type="checkbox"/> FLCS	Immunoglobulin Free Light Chains, Serum
<input type="checkbox"/> MSMRT	Mayo Algorithmic Approach for Stratification of Myeloma and Risk-Adapted Therapy Report Bone Marrow
<input type="checkbox"/> NGPCM	MayoComplete Plasma Cell Myeloma, Next-Generation Sequencing
<input type="checkbox"/> MRDMM	Multiple Myeloma Minimal Residual Disease by Flow, Bone Marrow

<input type="checkbox"/> MFCDF	Myeloma, High Risk with Reflex Probes, Diagnostic FISH Evaluation, Fixed Cell Pellet
<input type="checkbox"/> MSMRD	Myeloma Stratification and Risk-Adapted Therapy with Reflex to Minimal Residual Disease, Bone Marrow
<input type="checkbox"/> QMPSS	Monoclonal Protein Study, Quantitative, Serum
<input type="checkbox"/> PBLI	Plasma Cell Assessment, Blood
<input type="checkbox"/> PCPRO	Plasma Cell DNA Content and Proliferation, Bone Marrow
<input type="checkbox"/> PCPDS	Plasma Cell Proliferative Disorder, High Risk with Reflex Probes, Diagnostic FISH Evaluation, Bone Marrow
<input type="checkbox"/> PLASF	Plasma Cell Proliferative Disorder, FISH, Tissue